Post COVID Mucormycosis- A Narrative Review
Published: February 1, 2023 | DOI: https://doi.org/10.7860/JCDR/2023/59617.17471
Sakshi Dinesh Firke, Prasad Deshmukh
1. Student, Department of Ear, Nose and Throat, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, Maharashtra, India.
2. Professor and Head, Department of Ear, Nose and Throat, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, Maharashtra, India.
Correspondence
Sakshi Dinesh Firke,
4, Shanti Nagar, Yawal Road, Bhusawal, Maharashtra, India.
E-mail: hemakshiddf@gmail.com
Mucormycosis is an Acute Invasive Fungal Rhinosinusitis (AIFR). Omnipresent fungi and their interaction with humans are both boon and a bane. Fungal rhinosinusitis is now becoming an alarming situation in today’s world, especially in India. It can be classified further into invasive or non invasive and acute or chronic. Categorisation helps us with its diagnosis and management. The invasion of the hyphae portrays mucormycosis into sinus tissue within less than four weeks. It comes with various predisposing factors such as underlying systemic disease, drug therapy, transplantation, and local lesion. Clinical manifestations such as headache, sinonasal congestion, black lesions on the nasal bridge, and facial inflammation associated with pain are prevalent in immunocompromised patients. Crucial steps such as early identification, definite treatment with a multidisciplinary integrated approach of various departments such as ENT, medicine, and radiology should be made. Intraorbital and intracranial complications can be prevented by treating disease process in the early stage.
[
FULL TEXT ] | [ PDF]